



G00002

10 APR 2003

WO 00/37452


- 1 -

PCT/EP99/09335

Sulfonyloxazolamines as therapeutic active compounds

The invention relates to sulfonyloxazolamines of the general formula I

5



I,

in which

- R¹, R² each independently of one another are H, A, -(CH₂)_n-Ar or alkenyl having 2 to 6 C atoms,
- 10 R¹ and R² together are also a mononuclear saturated heterocycle having 1 to 2 N, O and/or S atoms,
- Z, is H, A, CF₃, NO₂, Hal, OH, OA, NH₂, NHA or NA₂,
- 15 A is alkyl having 1 to 6 C atoms,
- Ar is phenyl which is mono- or di-substituted by Z,
- Hal is F, Cl, Br or I,
- n is 1 or 2,
- 20 or their physiologically acceptable salts or solvates as therapeutic active compounds.

The invention furthermore relates to the use of the sulfonyloxazolamines of the general formula I as therapeutic active compounds.

- 25 The invention also relates to the use of the sulfonyloxazolamines of the general formula I for the production of pharmaceutical preparations in the control of disorders of the central nervous system.

- 30 Some compounds of the general formula I are known from various earlier publications. Thus, the



166166

preparation of the compounds of the formula I is described in V. A. Chervonyi et al., *Ukr. Khim. Zh.* (Russ. Ed.) **1991**, 57(4), 415-418 or V. A. Chervonyi et al., *Zh. Org. Khim.* **1988**, 24(2), 453-4 corresponding to V. A. Chervonyi et al., *J. Org. Chem. USSR* (Engl. transl.) **1988**, 24, 401. More detailed publications with respect to the pharmacological efficacy of the compounds of the formula I are not available in the prior art.

10 The invention was based on the object of finding novel useful properties of sulfonyloxazolamines, in particular those which confirm the compounds to be therapeutic active compounds and/or can lead to the use of the sulfonyloxazolamines as
15 therapeutic active compounds and/or to the production of pharmaceutical preparations.

 It has been found that the compounds of the formula I and their pharmacologically active salts surprisingly have a selective affinity for 5-HT6
20 receptors, together with good tolerability. They exhibit 5-HT6-antagonistic or 5-HT6 agonistic actions.

 5-HT6 receptors form a subfamily of 5-HT receptors. The neurotransmitter 5-hydroxytryptamine (5-HT), also known as serotonin, is an important
25 regulating neurotransmitter in the brain, whose actions are assisted by a family of receptors which, at the current level of knowledge, contain 13 G protein-coupled receptors and an ion channel.

 The greatest density of the serotonin 5-HT6
30 receptors in the brain is found in the olfactory tubercle, in the nucleus accumbens, in the striatum, in the dentate gyrus and in the CA1-3 regions of the hippocampus. These regions are involved to a particular extent in psychiatric disorders such as, for example,
35 schizophrenia or depression. Moreover, it is known from animal experiments that the administration of 5-HT6 antisense oligonucleotides causes a behavioural syndrome which corresponds to that of dopamine

10 APR 2003

agonists. Furthermore, hyperactivity of the dopaminergic neurotransmitter system in schizophrenia (dopamine hypothesis of schizophrenia) is pathophysiologically confirmed. However, dysfunctions of the dopamine system in various forms of depression have been demonstrated. Of the established or alternatively newer therapeutics which are employed in clinical practice for the treatment of these psychiatric disorders, a large number moreover bind to the 5-HT₆ receptor. The atypical neuroleptics (e.g. clozapine) and the tricyclic antidepressants (e.g. amitriptyline) may be mentioned here in particular.

Moreover, it was found in animal experimental investigations that 5-HT₆ receptors in the brain control cholinergic neurotransmission. Cholinergics are employed in disorders with memory disturbances such as, for example, Alzheimer's disease.

For these reasons, it can be concluded that there is an involvement of the 5-HT₆ receptor in psychiatric and neurological disorders such as, preferably, schizophrenia, depression and Alzheimer's.

The compounds of the formula I and their physiologically acceptable salts are therefore suitable as therapeutic active compounds for disorders of the central nervous system. The compounds of the formula I and their physiologically acceptable salts or solvates are particularly suitable for the treatment of psychoses, schizophrenia, manic depression (B. L. Roth et al., *J. Pharmacol. Exp. Ther.* **1994**, 268, 1403-1410), depression (D. R. Sibley et al., *Mol. Pharmacol.* **1993**, 43, 320-327), neurological disorders (A. Bourson et al., *J. Pharmacol. Exp. Ther.* **1995**, 274, 173-180), memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease (A. J. Sleight et al., *Neurotransmissions* **1995**, 11, 1-5), bulimia, anorexia nervosa or other eating disorders, compulsive acts or of premenstrual syndrome.

propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-aminophenyl, o-, m- or p-N,N-dimethylaminophenyl, o-, m- or p-nitrophenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl, o-,
 5 m- or p-ethoxyphenyl, o-, m-, p-trifluoromethylphenyl, o-, m- or p-fluorophenyl, o-, m- or p-chlorophenyl, o-, m- or p-bromophenyl, furthermore preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dimethylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dihydroxyphenyl, 2,3-, 2,4-,
 10 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dimethoxyphenyl.

Phenyl, o- or p-methylphenyl, o- or p-chlorophenyl, p-bromophenyl, p-methoxyphenyl or 2,4-dichlorophenyl is particularly preferred for Ar.

In $-(CH_2)_n-Ar$, Ar has one of the preferred meanings indicated beforehand, where n can be 1 or 2. Benzyl is particularly preferred for $-(CH_2)_n-Ar$.

20 Hal is preferably fluorine, chlorine or bromine.

Z is H, A, CF_3 , NO_2 , Hal, OH, OA, NH_2 , NHA or NA_2 , where A and Hal have one of the preferred meanings indicated beforehand. H, methyl, chlorine, bromine or
 25 methoxy is particularly preferred for Z.

n is preferably 1 or 2, particularly preferably 1.

R^1 and R^2 are, independently of one another, H, A $-(CH_2)_n-Ar$ or alkenyl having 2 to 6 C atoms, where A, Ar, alkenyl and n have one of the preferred or
 30 particularly preferred meanings indicated beforehand.

In addition, R^1 and R^2 together are also a mononuclear saturated heterocycle having 1 to 2 N, O and/or S atoms.

35 R^1 and R^2 together are preferably tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, tetrahydro-1-, -3- or -4-pyrazolyl,

10 APR 2003

1-, 2-, 3- or 4-piperidinyl, 1-, 2-, 3- or
4-perhydroazepinyl, 2-, 3- or 4-morpholinyl,
tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-
5 dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-
pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl
or 1-, 2- or 3-piperazinyl. 1-Piperidinyl or 4-
morpholinyl is particularly preferred for R¹ and R²
together.

For the subject of the invention, of the
10 therapeutic active compounds of the formula I or their
physiologically acceptable salts or solvates, of the
use of the compounds of the formula I or their
physiologically acceptable salts or solvates as
15 therapeutic active compounds or of the production of a
pharmaceutical preparation for the treatment of
disorders of the central nervous system, in particular
those compounds of the formula I are preferred in which
at least one of the radicals mentioned has one of the
20 preferred or particularly preferred meanings indicated
above. Some preferred groups of compounds can be
expressed by the following subformulae Ia to Ic, which
correspond to the formula I and in which the radicals
not described in greater detail have the meaning
indicated in the formula I, but in which


25

in Ia R¹ and R² in each case independently of one
another are H, A, -(CH₂)_n-Ar or alkenyl having 2
to 6 C atoms;

30

in Ib R¹ and R² in formula I together are 1-
piperidinyl;

10 APR 2003




Ib

or

5

in Ic R^1 and R^2 in formula I together are 4-morpholinyl;



Ic

10 The following compounds of the formulae Ia, Ib and Ic are particularly preferred for use according to Claim 1:

- 15 dimethyl-[2-phenyl-4-(toluene-4-sulfonyl)oxazol-5-yl]-amine;
 [2-(2,4-dichlorophenyl)-4-(toluene-4-sulfonyl)oxazol-5-yl]dimethylamine;
 benzyl-[2-(2,4-dichlorophenyl)-4-(toluene-4-sulfonyl)-oxazol-5-yl]amine;
 20 methyl-[4-(toluene-4-sulfonyl)-2-*p*-tolylloxazol-5-yl]-amine;
 benzyl-[4-(4-chlorobenzenesulfonyl)-2-(2,4-dichlorophenyl)oxazol-5-yl]amine;

(4-benzenesulfonyl-2-*m*-tolylloxazol-5-yl)benzylamine;
[4-(4-chlorobenzenesulfonyl)-2-*p*-tolylloxazol-5-yl]-
dimethylamine;
(4-benzenesulfonyl-2-*o*-tolylloxazol-5-yl)methylamine;
5 benzyl-[4-(4-chlorobenzenesulfonyl)-2-(2-chlorophenyl)-
oxazol-5-yl]amine;
[4-benzenesulfonyl-2-(2,4-dichlorophenyl)oxazol-5-yl]-
benzylamine;
[4-benzenesulfonyl-2-(2,4-dichlorophenyl)oxazol-5-yl]-
10 dimethylamine;
[4-benzenesulfonyl-2-(2-chlorophenyl)oxazol-5-yl]-
dimethylamine;
1-[2-(2,4-dichlorophenyl)-4-(toluene-4-sulfonyl)-
oxazol-5-yl]piperidine;
15 1-[4-benzenesulfonyl-2-(2,4-dichlorophenyl)oxazol-5-
yl]piperidine;
1-[4-benzenesulfonyl-2-(2-chlorophenyl)oxazol-5-yl]-
piperidine;
4-[4-(toluene-4-sulfonyl)-2-*p*-tolylloxazol-5-yl]-
20 morpholine;
4-[4-(4-chlorobenzenesulfonyl)-2-*p*-tolylloxazol-5-yl]-
morpholine;
4-[4-(4-chlorobenzenesulfonyl)-2-phenylloxazol-5-yl]-
morpholine;
25 4-[4-(4-benzenesulfonyl)-2-(4-bromophenyl)oxazol-5-yl]-
morpholine;
4-[4-(4-benzenesulfonyl)-2-*m*-tolylloxazol-5-yl]-
morpholine;
4-[4-(4-benzenesulfonyl)-2-(4-methoxyphenyl)oxazol-5-
30 yl]morpholine;
4-[4-(4-benzenesulfonyl)-2-phenylloxazol-5-yl]-
morpholine;
allyl-(4-benzenesulfonyl-2-phenylloxazol-5-yl)amine;
4-[4-benzenesulfonyl-2-(2-chlorophenyl)oxazol-5-yl]-
35 morpholine;
(4-benzenesulfonyl-2-phenylloxazol-5-yl)dimethylamine;
(4-benzenesulfonyl-2-*m*-tolylloxazol-5-yl)dimethylamine;

benzyl-[2-phenyl-4-(toluene-4-sulfonyl)oxazol-5-yl]-
amine and

benzyl-[4-(toluene-4-sulfonyl)-2-m-tolyloxazol-5-yl]-
amine.

- 5 In relation to formula Ia, the following known
compounds are preferred for use as therapeutic active
compounds:

- 10 dimethyl-[2-phenyl-4-(toluene-4-sulfonyl)oxazol-5-yl]-
amine;
[2-(2,4-dichlorophenyl)-4-(toluene-4-sulfonyl)oxazol-5-
yl]dimethylamine;
benzyl-[2-(2,4-dichlorophenyl)-4-(toluene-4-sulfonyl)-
oxazol-5-yl]amine;
15 methyl-[4-(toluene-4-sulfonyl)-2-p-tolyloxazol-5-yl]-
amine;
benzyl-[4-(4-chlorobenzenesulfonyl)-2-(2,4-dichloro-
phenyl)oxazol-5-yl]amine;
(4-benzenesulfonyl-2-m-tolyloxazol-5-yl)benzylamine;
20 [4-(4-chlorobenzenesulfonyl)-2-p-tolyloxazol-5-yl]-
dimethylamine;
(4-benzenesulfonyl-2-o-tolyloxazol-5-yl)methylamine;
benzyl-[4-(4-chlorobenzenesulfonyl)-2-(2-chlorophenyl)-
oxazol-5-yl]amine;
25 [4-benzenesulfonyl-2-(2,4-dichlorophenyl)oxazol-5-yl]-
benzylamine;
allyl-(4-benzenesulfonyl-2-phenyloxazol-5-yl)amine;
(4-benzenesulfonyl-2-phenyloxazol-5-yl)dimethylamine;
(4-benzenesulfonyl-2-m-tolyloxazol-5-yl)dimethylamine;
30 benzyl-[2-phenyl-4-(toluene-4-sulfonyl)oxazol-5-yl]-
amine;
benzyl-[4-(toluene-4-sulfonyl)-2-m-tolyloxazol-5-yl]-
amine;
[4-benzenesulfonyl-2-(2,4-dichlorophenyl)oxazol-5-
35 yl]dimethylamine and
[4-benzenesulfonyl-2-(2-chlorophenyl)oxazol-5-yl]-
dimethylamine.

10 APR 2003

In relation to formula Ib, the following known compounds are preferred for use as therapeutic active compounds:

- 5 1-[2-(2,4-dichlorophenyl)-4-(toluene-4-sulfonyl)-
oxazol-5-yl]piperidine;
1-[4-benzenesulfonyl-2-(2,4-dichlorophenyl)oxazol-5-
yl]piperidine and
1-[4-benzenesulfonyl-2-(2-chlorophenyl)oxazol-5-yl]-
10 piperidine.

In relation to formula Ic, the following known compounds are preferred for use as therapeutic active compounds:

- 15 4-[4-(toluene-4-sulfonyl)-2-p-tolyloxazol-5-yl]-
morpholine;
4-[4-(4-chlorobenzenesulfonyl)-2-p-tolyloxazol-5-yl]-
morpholine;
4-[4-(4-chlorobenzenesulfonyl)-2-phenyloxazol-5-yl]-
20 morpholine;
4-[4-(4-benzenesulfonyl)-2-(4-bromophenyl)oxazol-5-
yl]morpholine;
4-[4-(4-benzenesulfonyl)-2-m-tolyloxazol-5-yl]-
morpholine;
25 4-[4-benzenesulfonyl-2-(2-chlorophenyl)oxazol-5-yl]-
morpholine;
4-[4-(4-benzenesulfonyl)-2-(4-methoxyphenyl)oxazol-5-
yl]morpholine and
4-[4-(4-benzenesulfonyl)-2-phenyloxazol-5-yl]-
30 morpholine.

The invention furthermore relates to the use of the following compounds, selected from the group

- a) dimethyl-[2-phenyl-4-(toluene-4-sulfonyl)oxazol-5-
yl]amine,
35 b) [2-(2,4-dichlorophenyl)-4-(toluene-4-sulfonyl)-
oxazol-5-yl]dimethylamine,
c) benzyl-[4-(4-chlorobenzenesulfonyl)-2-(2-
chlorophenyl)oxazol-5-yl]amine,

10 APR 2003


- d) (4-benzenesulfonyl-2-o-tolyloxazol-5-yl)-
methylanine,
- e) benzyl-[2-(2,4-dichlorophenyl)-4-(toluene-4-
sulfonyl)oxazol-5-yl]amine,
- 5 f) [4-benzenesulfonyl-2-(2,4-dichlorophenyl)oxazol-5-
yl]benzylamine,
- g) [4-benzenesulfonyl-2-(2,4-dichlorophenyl)oxazol-5-
yl]dimethylamine,

or one of their physiologically acceptable salts or
10 solvates as therapeutic active compounds against
disorders of the central nervous system.

The compounds of the formula I are generally
commercially obtainable or can be synthesized according
to the following synthesis scheme (for this cf. V. A.
15 Chervonyi et al., *Ukr. Khim. Zh.* (Russ. Ed.) **1991**,
57(4), 415-418 or V. A. Chervonyi et al., *Zh. Org.*
Khim. **1988**, 24(2), 453-4 corresponding to V. A.
Chervonyi et al., *J. Org. Chem. USSR* (Engl. transl.)
1988, 24, 401).

10 APR 2003

Synthesis scheme:



10 APR 2003

In the synthesis scheme shown beforehand, the starting material of the formula II is reacted with trichloroacetate to give the compound III. The reaction with thionyl chloride and subsequently with the sodium sulfinate of the formula V generates an aryl vinyl sulfone of the formula VI, which cyclizes to give the sulfonyloxazolamines of the formula I by reaction with an amine of the formula VII. In this connection, the substituents Ar, Z, R¹ and R² of the formula II to VII have preferred or particularly preferred meanings as indicated beforehand.

The suitable reaction conditions of the reactions mentioned from the synthesis scheme are known from the references V. A. Chervonyi et al., *Ukr. Khim. Zh.* (Russ. Ed.) **1991**, 57(4), 415-418 or V. A. Chervonyi et al., *Zh. Org. Khim.* **1988**, 24(2), 453-4 corresponding to V. A. Chervonyi et al., *J. Org. Chem. USSR* (Engl. transl.) **1988**, 24, 401, or from standard works such as, for example, Houben-Weyl, *Methoden der organischen Chemie* [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart. In this case, use can also be made of variants which are known per se, but not mentioned here in greater detail.

A base of the formula I can be converted into the associated acid addition salt using an acid, for example by reaction of equivalent amounts of the base and of the acid in an inert solvent such as ethanol and subsequent evaporation. For this reaction, suitable acids are in particular those which yield physiologically acceptable salts. Thus inorganic acids can be used, e.g. sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, in addition organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g. formic acid, acetic acid, propionic acid, pivalic acid,

diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, 5 methane- or ethanesulfonic acid, p-toluenesulfonic acid, naphthalenemono- and disulfonic acids or lauryl sulfuric acid. Salts with physiologically unacceptable acids, e.g. picrates, can be used for the isolation and/or purification of the compounds of the formula I.

10 The binding of the compounds of the formula I to 5-HT₆ receptors was determined as follows:

The substances to be tested were dissolved in DMSO at a concentration of 1 mM and diluted to the desired concentrations (0.1 nM to 10 μ M) using test buffer 15 (20 mM HEPES, 0.1% ascorbic acid, adjusted to pH 7.4 using NaOH).

20 μ l of the respective substance solution were incubated at 37°C for 1 hour with 80 μ l of ³H-LSD solution (TRK-1041, Amersham Pharmacia, Freiburg, spec. act. 80-90 Ci/mMol, 1 nM in the batch) and 100 μ l of membrane suspension (5-HT₆ receptors, RB-HS6, Biotrend, Cologne, 25-30 μ g of protein). The reaction mixture was filtered through GFB filters (Whatman) which had been pretreated with 0.1% aqueous polyethyleneimine solution 25 for 1 hour. The filters were washed 3 times with 3 ml of test buffer, the filters [sic] transferred to minivials and, after addition of Ultima Gold (Packard, Frankfurt), the radioactivity was determined in a liquid scintillation counter. The evaluation and IC₅₀ 30 determination was carried out by means of in-house programs in RS1 (BBN Software Corporation).

The compounds of the formula I have a selective affinity for 5-HT₆ receptors having an inhibition constant IC₅₀ of less than 4 μ mol/l.

35 The invention furthermore relates to the use of the compounds of the general formula I for the production of a pharmaceutical preparation for controlling disorders of the central nervous system.

The invention furthermore relates to the use of compounds of the general formula I for the production of a pharmaceutical preparation for the treatment of psychoses, schizophrenia, manic depression, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, bulimia, anorexia nervosa or other eating disorders, compulsive acts or premenstrual syndrome.

The invention furthermore relates to pharmaceutical preparations for the control of disorders of the central nervous system, comprising at least one compound of the formula I or one of its physiologically acceptable salts or solvates.

These preparations can be used as pharmaceuticals in human or veterinary medicine. Possible vehicles are organic or inorganic substances which are suitable for enteral (e.g. oral), or parenteral administration or topical application and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc or petroleum jelly. Tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops, in particular, are used for oral administration, suppositories are used for rectal administration, solutions, preferably oily or aqueous solutions, in addition suspensions, emulsions or implants, are used for parenteral administration, and ointments, creams or powders are used for topical application. The novel compounds can also be lyophilized and the lyophilizates obtained used, for example, for the production of injection preparations. The preparations indicated can be sterilized and/or can contain excipients such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer

substances, colorants, flavourings and/or other active compounds, e.g. one or more vitamins.

The invention also relates to a process for the production of these pharmaceutical preparations, which is characterized in that a compound of the formula I or one of its physiologically tolerable salts or solvates is brought into a suitable dose form together with at least one solid, liquid or semiliquid vehicle or excipient and, if appropriate, in combination with one or more other active compound.

The compounds of the formula I and their physiologically acceptable salts or solvates can be employed for the control of disorders of the central nervous system.

The substances according to the invention are as a rule administered here in a dose of preferably between approximately 1 and 500 mg, in particular between 5 and 100 mg, per dose unit. The daily dose is preferably between approximately 0.02 and 10 mg/kg of body weight. The specific dose for each patient, however, depends on all sorts of factors, for example on the efficacy of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, and on the excretion rate, pharmaceutical combination and severity of the particular disorder to which the therapy applies. Oral administration is preferred.

The following examples relate to pharmaceutical preparations:

Example A: Injection vials

A solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water using 2N hydrochloric acid, sterile-filtered, filled into injection vials, lyophilized under sterile conditions and aseptically sealed. Each injection vial contains 5 mg of active compound.

Example B: Suppositories

A mixture of 20 g of an active compound of the formula I is fused with 100 g of soya lecithin and 1400 g of cocoa butter, poured into moulds and allowed to cool. Each suppository contains 20 mg of active compound.

Example C: Solution

A solution of 1 g of an active compound of the formula I, 9.38 g of $\text{NaH}_2\text{PO}_4 \cdot 2 \text{H}_2\text{O}$, 28.48 g of $\text{Na}_2\text{HPO}_4 \cdot 12 \text{H}_2\text{O}$ and 0.1 g of benzalkonium chloride in 940 ml of double-distilled water is prepared. It is adjusted to pH 6.8, made up to 1 l and sterilized by irradiation. This solution can be used in the form of eye drops.

Example D: Ointment

500 mg of an active compound of the formula 1 are mixed with 99.5 g of petroleum jelly under aseptic conditions.

Example E: Tablets

A mixture of 1 kg of active compound of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 g of talc and 0.1 kg of magnesium stearate is compressed to give tablets in a customary manner such that each tablet contains 10 mg of active compound.

Example F: Coated tablets

Analogously to Example E, tablets are pressed and are then coated in a customary manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.

Example G: Capsules

2 kg of active compound of the formula I are filled into hard gelatin capsules in a customary manner such that each capsule contains 20 mg of the active compound.


10 APR 2003

Example H: Ampoules

A solution of 1 kg of active compound of the formula I in 60 ml of double-distilled water is sterile-filtered, filled into ampoules, lyophilized
5 under sterile conditions and aseptically sealed. Each ampoule contains 10 mg of active compound.

Claims

1. A compound of formula I'



in, which

R^1 , R^2 each independently of one another are H, A, $-(CH_2)_n$ -Ar or alkenyl having 2 to 6 atoms,

R^1 and R^2 together are also a mononuclear saturated heterocycle having 1 or 2 N, O and/or S atoms,

Z is CF_3 , NO_2 , Hal, OH, NH_2 , NHA or NA_2 ,

A is alkyl having 1 to 6 C atoms,


Ar is phenyl which is mono- or disubstituted by Z,

Hal is F, Cl, Br or I,

n is 1 or 2

or a physiologically acceptable salt or solvate thereof.

2. A method for treating a disorder of the central nervous system, comprising administering an effective amount of a compound of formula I to a patient in need thereof



in, which

R^1 , R^2 each independently of one another are H, A, $-(CH_2)_n$ -Ar or alkenyl having 2 to 6 atoms,

1 0 APR 2003

R^1 and R^2 together are also a mononuclear saturated heterocycle having 1 or 2 N, O and/or S atoms,

Z is H, A, CF_3 , NO_2 , Hal, OH, NH_2 , NHA or NA_2 ,


A is alkyl having 1 to 6 C atoms,

Ar is phenyl which is mono- or disubstituted by Z,

Hal is F, Cl, Br or I,

n is 1 or 2.

3. A method for the treatment of psychoses, schizophrenia, manic depression, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, bulimia, anorexia nervosa, eating disorders, compulsive acts or premenstrual syndrome, comprising administering an effective amount of a compound of formula I to patient in need thereof



in, which

R^1 , R^2 each independently of one another are H, A, $-(CH_2)_n$, $-Ar$ or alkenyl having 2 to 6 atoms,

R^1 and R^2 together are also a mononuclear saturated heterocycle having 1 or 2 N, O and/or S atoms,

Z is H, A, CF_3 , NO_2 , Hal, OH, NH_2 , NHA or NA_2 ,


A is alkyl having 1 to 6 C atoms,

Ar is phenyl which is mono- or disubstituted by Z,

Hal is F, Cl, Br or I,

n is 1 or 2.

4. A pharmaceutical composition, comprising a compound of formula I



in, which

R^1 , R^2 each independently of one another are H, A, $-(CH_2)_n$ --Ar or alkenyl having 2 to 6 atoms,

R^1 and R^2 together are also a mononuclear saturated heterocycle having 1 or 2 N, O and/or S atoms,

Z is H, A, CF_3 , NO_2 , Hal, OH, NH_2 , NHA or NA_2 ,

A is alkyl having 1 to 6 C atoms,

Ar is phenyl which is mono- or disubstituted by Z,


Hal is F, Cl, Br or I,

n is 1 or 2

and a pharmaceutically acceptable carrier.

5. A process for the production of a pharmaceutical composition according to claim 4, comprising bringing a compound of the formula I or one of its physiologically tolerable salts or solvates into a suitable dose form together with at least one solid, liquid or semiliquid vehicle or excipient and, optionally, one or more other active compounds.

6. A method for treating a disease mediated by 5-HT₆ receptors, comprising administering an effective amount of a compound of formula I to patient in need thereof



in, which

R^1 , R^2 each independently of one another are H, A, $-(CH_2)_n$ --Ar or alkenyl having 2 to 6 atoms,

R^1 and R^2 together are also a mononuclear saturated heterocycle having 1 or 2 N, O and/or S atoms,

Z is H, CF_3 , NO_2 , Hal, OH, NH_2 , NHA or NA_2 ,

A is alkyl having 1 to 6 C atoms,

Ar phenyl which is mono- or disubstituted by Z,

Hal is F, Cl, Br or I,

n is 1 or 2.

7. A method according to claim 6, comprising administering

- a) dimethyl-[2-phenyl-4-(toluene-4-sulfonyl)oxazol-5-yl]amine,
- b) [2-(2, 4-dichlorophenyl)-4-(toluene-4-sulfonyl)oxazol-5-yl]dimethylamine,
- c) benzyl-[4-(4-chlorobenzenesulfonyl)-2-(2-chlorophenyl)oxazol-5-yl]amine,
- d) 4-benzenesulfonyl-2-o-tolylloxazol-5-yl-methylamine,
- e) benzyl-[2-(2, 4 dichlorophenyl)-4-(toluene-4-sulfonyl)oxazol-5-yl] amine,
- f) [4-benzenesulfonyl-2-(2-, 4 dichlorophenyl)oxazol-5-yl]benzylamine, or
- g) [4-benzenesulfonyl-2-(2-, 4 dichlorophenyl)oxazol-5-yl]dimethylamine.